Skip to main
CNTA

CNTA Stock Forecast & Price Target

CNTA Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Centessa Pharmaceuticals PLC exhibits strong fundamentals bolstered by its promising pipeline, particularly with ORX750, which is positioned to potentially achieve best-in-class status for treating Narcolepsy Type 1 and other sleep disorders. The company reported a robust cash position of approximately $405 million as of the end of Q2 2025, providing ample runway to support its operations and ongoing clinical development well into mid-2027. Furthermore, the anticipated market dynamics for orexin agonists, alongside a substantial estimated sales potential of around $3.6 billion, underline a significant upside opportunity that enhances the positive outlook for Centessa Pharmaceuticals's stock.

Bears say

Centessa Pharmaceuticals faces significant commercial and competitive risks, primarily due to potential market limitations for its pipeline assets stemming from negotiations with payors and competitive pressures. The presence of high non-responder rates and waning efficacy observed in related clinical programs introduces further uncertainty regarding the effectiveness and market acceptance of its lead candidate, ORX750, for Narcolepsy Type 1. Additionally, the conservative market analysis indicates that the company's current valuation may not accurately reflect the broader potential for its therapeutics, particularly given the implications of late-day efficacy issues and the high variability caused by administration compliance.

CNTA has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Centessa Pharmaceuticals PLC (CNTA) Forecast

Analysts have given CNTA a Buy based on their latest research and market trends.

According to 10 analysts, CNTA has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Centessa Pharmaceuticals PLC (CNTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.